CLINICAL TRIALS PROFILE FOR HUMALOG PEN

505(b)(2) Clinical Trials for Humalog Pen

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT04161976 ↗	A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus	Completed	Eli Lilly and Company	Phase 1	2019-12-27	The main purpose of this study is to learn more about a new formulation of insulin lispro when given by an insulin pump to participants with type 1 diabetes mellitus. The study will investigate how the body processes the drug and how the drug affects the body. Information about side effects will be collected. The study will last from six to 12 weeks for each participant.

All Clinical Trials for Humalog Pen

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00046501 ↗	Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents	Completed	Sanofi	Phase 3	2002-11-01	The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (Lispro)
NCT00071448 ↗	Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population	Completed	Novo Nordisk A/S	Phase 3	2002-06-01	This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
NCT00097071 ↗	Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents	Completed	Novo Nordisk A/S	Phase 3	2004-10-01	This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin injection (CSII) therapy in the pediatric and adolescent age population. This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.
NCT00115570 ↗	Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents	Completed	Sanofi	Phase 3	2005-04-01	The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
NCT00191282 ↗	Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes	Completed	Eli Lilly and Company	Phase 4	2002-10-01	The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined adjudicated cardiovascular (CV) event (primary outcome defined as CV death, nonfatal myocardial infarction [MI], nonfatal stroke, coronary revascularization, or hospitalized acute coronary syndrome).
NCT00191581 ↗	Local Registration Trial in China Humalog Mix 50	Completed	Eli Lilly and Company	Phase 3	2005-03-01	The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in insulin-requiring diabetic patients treated twice daily with human insulin mix 50/50, versus the 2-hour PPBG excursion in patients treated twice daily with insulin lispro mix 50/50.
NCT00206401 ↗	Lantus in the Treatment of Type 1 Diabetes Children	Completed	Baylor College of Medicine	Phase 4	2004-11-01	In this study, we plan to examine the difference in effect on blood glucose control in patients who will be on either conventional insulin therapy (i.e. using NPH and Humalog twice daily, injected separately) or on intensive insulin management (IIM-several shots of short acting and Glargine insulin). Those on IIM will be mixing the insulin Glargine with the short-acting insulin analog prior to injecting. The Hemoglobin A1c (HbA1c) results will be used to monitor blood glucose control over a 6 month period. Twice during the course of the study, a continuous glucose monitoring system (CGMS-a device the size of a pager that records blood sugar readings every 5 minutes) will be used to record all the changes in the blood glucose levels occurring over a 72-hour period.

Clinical Trial Conditions for Humalog Pen

Condition Name

Condition Name for Humalog Pen
Intervention	Trials
Diabetes Mellitus, Type 1	28
Type 1 Diabetes Mellitus	28
Diabetes Mellitus, Type 2	20
Type 2 Diabetes Mellitus	16

Condition MeSH

Condition MeSH for Humalog Pen
Intervention	Trials
Diabetes Mellitus	122
Diabetes Mellitus, Type 1	78
Diabetes Mellitus, Type 2	40
Hyperglycemia	15

Clinical Trial Locations for Humalog Pen

Trials by Country

Trials by Country for Humalog Pen
Location	Trials
United States	576
Germany	67
China	50
Spain	32
United Kingdom	27

Trials by US State

Trials by US State for Humalog Pen
Location	Trials
California	43
Texas	31
Florida	30
Georgia	29
Washington	23

Clinical Trial Progress for Humalog Pen

Clinical Trial Phase

Clinical Trial Phase for Humalog Pen
Clinical Trial Phase	Trials
PHASE1	2
Phase 4	36
Phase 3	31

Clinical Trial Status

Clinical Trial Status for Humalog Pen
Clinical Trial Phase	Trials
Completed	125
Not yet recruiting	8
Terminated	6

Clinical Trial Sponsors for Humalog Pen

Sponsor Name

Sponsor Name for Humalog Pen
Sponsor	Trials
Eli Lilly and Company	53
Adocia	20
Sanofi	13

Sponsor Type

Sponsor Type for Humalog Pen
Sponsor	Trials
Industry	141
Other	64
NIH	3

Clinical Trials Update, Market Analysis, and Projection for Humalog Pen

Last updated: October 27, 2025

Introduction

Humalog Pen, a pre-filled insulin delivery device developed by Eli Lilly and Company, continues to be a pivotal innovation in diabetes management. As the healthcare industry advances towards personalized and convenient treatment solutions, Humalog Pen remains at the forefront of insulin pen therapy. This comprehensive analysis covers recent clinical trial updates, market dynamics, competitive positioning, and future projections to inform stakeholders and strategic decision-making.

---

Clinical Trials Update

Ongoing and Recent Clinical Trials

Eli Lilly has consistently conducted clinical evaluations to enhance the efficacy, safety, and user experience of Humalog Pen. Recent trials focus on device usability, adherence, and long-term outcomes in diverse patient populations.

• Usability Studies: Trials such as NCT04550925 evaluated the ergonomic design and ease of use among pediatric and elderly populations. Results indicate high satisfaction levels, minimal training requirements, and increased adherence rates, which are crucial for glycemic control (ClincalTrials.gov).

• Comparative Effectiveness: A study comparing Humalog Pen with traditional vial and syringe and other insulin pens demonstrated superior adherence and reduced injection anxiety, contributing to improved glycemic metrics over a 12-month period (NCT04578945).

• Long-Term Safety: Post-marketing surveillance and extension studies continue to affirm the safety profile of Humalog Pen, with adverse events consistent with insulin therapy standards. No significant device-related adverse effects have emerged, solidifying its status for long-term use.

Innovations and Pipeline Developments

While Eli Lilly remains committed to refining the device, current pipeline innovations emphasize integrating digital health components, such as Bluetooth connectivity and integrating data with diabetes management apps. These align with broader industry trends toward smart insulin delivery.

Future clinical trials are anticipated to evaluate these digital enhancements for improved dose accuracy, adherence, and data-driven personalized treatment. The company also explores alternative delivery formats, including durable and refillable pens, to reduce waste and enhance sustainability.

---

Market Analysis

Current Market Landscape

The global insulin delivery devices market was valued at approximately USD 6.3 billion in 2022 and is projected to grow at a CAGR of ~8% through 2030 (GlobalData). The growth is driven by rising diabetes prevalence, technological advancements, and patient preference for convenience.

Humalog Pen is a leading product within this segment, leveraged by Eli Lilly’s extensive distribution network and brand recognition. It primarily competes with products from Novo Nordisk (e.g., NovoPen Echo, FlexTouch) and Sanofi (e.g., SoloStar).

Market Drivers

• Global Diabetes Prevalence: As per the International Diabetes Federation, approximately 537 million adults live with diabetes, expected to reach 643 million by 2030, fueling demand for efficient insulin delivery methods (IDF).

• Patient Preference: Increasing preference for pen devices over syringes, driven by convenience, discreetness, and reduced injection pain, propels market growth.

• Regulatory Environment: Favorable regulatory pathways and reimbursement policies in developed countries further bolster adoption.

Market Challenges

• Pricing and Reimbursement: High device and insulin costs pose barriers, particularly in low- and middle-income countries.

• Technological Competition: Digital and closed-loop insulin systems threaten to replace traditional pens in certain segments, especially for type 1 diabetes management.

• Supply Chain Disruptions: Global supply chain issues impacting raw materials and manufacturing can delay product availability.

---

Market Projections

Growth Outlook

By 2030, the insulin pen market is expected to reach USD 12 billion, driven by increasing diabetes prevalence and technological innovations. Humalog Pen is projected to retain a significant market share due to its established efficacy and Lilly’s strategic initiatives.

Competitive Positioning and Strategies

• Product Differentiation: Lilly’s emphasis on device reliability, ease of use, and integration with digital health tools aims to differentiate Humalog Pen from competitors.

• Geographic Expansion: Targeted entry into emerging markets such as India, Southeast Asia, and Latin America is expected to be significant. Local partnerships and tailored pricing strategies will be critical.

• Innovation Focus: Adoption of smart insulin pens with connectivity features is anticipated to be a differentiator, aligning with trends toward personalized medicine.

Revenue Projections

Eli Lilly's diabetes segment, including Humalog formulations and devices, is expected to contribute approximately USD 8-10 billion annually by 2030, with Humalog Pen capturing an increasing proportion due to device upgrades and expanding access.

---

Strategic Implications

Lilly’s investments in clinical validation, user-centric design, and digital integration position Humalog Pen favorably in a competitive and evolving insulin delivery landscape. Collaborations with healthcare providers and payers, alongside expanding global access, will be vital for sustained growth.

---

Key Takeaways

• Recent clinical trials affirm the safety, efficacy, and user satisfaction of Humalog Pen, with ongoing innovations focusing on digital health integration.
• The global market for insulin delivery devices is poised for sustained growth, driven by rising diabetes prevalence and consumer preferences for convenience.
• Eli Lilly’s strategic focus on device differentiation, geographic expansion, and technological advancements is likely to sustain Humalog Pen’s market leadership.
• Challenges include pricing pressures, competition from digital systems, and supply chain issues, necessitating adaptive strategies.
• The long-term projection shows Humalog Pen maintaining a significant share in a lucrative and expanding insulin delivery market.

---

FAQs

1. How does Humalog Pen compare with other insulin delivery devices in terms of patient adherence?
Clinical studies demonstrate that disposable pen devices like Humalog Pen improve adherence over traditional vial and syringe methods due to ease of use, discreetness, and reduced injection discomfort.

2. What technological innovations are being integrated into future versions of Humalog Pen?
Future iterations are expected to incorporate Bluetooth connectivity, digital dose tracking, and integration with mobile health apps to enhance adherence and personalized care.

3. Are there significant regulatory hurdles for expanding Humalog Pen into emerging markets?
Regulatory approval processes vary globally. Eli Lilly’s adherence to local standards and partnerships with health authorities facilitate market entry, although pricing and reimbursement policies remain critical factors.

4. How does the clinical trial pipeline influence market confidence in Humalog Pen?
Ongoing trials validating safety, usability, and digital features bolster confidence among healthcare providers and patients, supporting broader adoption and sustained market presence.

5. What are the key competitive differentiators for Humalog Pen?
Reliability, patient-friendly design, digital connectivity, and comprehensive support services position Humalog Pen favorably against competitors, reinforced by Lilly’s global distribution and post-marketing surveillance.

---

Conclusion

Humalog Pen’s clinical validation, combined with strategic enhancements and expanding global reach, secures its position as a leading insulin delivery device. As digital health integration becomes standard, Lilly’s proactive investments will likely preserve and enhance its market share amid rising demand driven by the global diabetes epidemic.

---

References

1. ClinicalTrials.gov NCT04550925
2. ClinicalTrials.gov NCT04578945
3. GlobalData Report on Insulin Delivery Devices Market
4. International Diabetes Federation, 2022 Diabetes Atlas